Privia Health Group, Inc. — Form 8-K Summary
Business context and reporting period
Privia Health Group, Inc. filed a Form 8-K dated May 22, 2024, reporting the results of its 2024 Annual Meeting of Stockholders and related amendments to its governing documents. The filing does not report operating or financial results for a quarterly or annual reporting period.
Financial and operating metrics
The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, liquidity, guidance, or other operating metrics.
Material changes and annual meeting results
- Stockholders elected four Class II directors—Thomas McCarthy, Parth Mehrotra, Dr. Jaewon Ryu, and William (Bill) Sullivan—to terms expiring at the 2027 annual meeting, subject to earlier termination of service.
- Stockholders approved, on a non-binding advisory basis, the compensation of the named executive officers.
- Stockholders ratified PricewaterhouseCoopers LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2024.
- Stockholders approved amendments to remove supermajority voting provisions from the Charter.
- Stockholders approved amendments permitting the removal or limitation of officer personal liability to the extent allowed under Delaware law.
- Following the meeting, the Company filed its Second Amended and Restated Certificate of Incorporation with the Delaware Secretary of State.
- The Board adopted Fourth Amended and Restated Bylaws, including changes conforming to the amended Charter and other ministerial and clarifying revisions.
Guidance, outlook, risks, and unusual items
No financial guidance, outlook, contingencies, litigation matters, or unusual financial items are disclosed in the filing. The principal governance change is the removal of supermajority voting requirements and the adoption of permitted officer exculpation provisions. The full Charter and Bylaws should be reviewed for the precise scope and effect of these amendments.
Key facts for investors to verify
- Review Exhibits 3.1 and 3.2 for the complete amended Charter and Bylaws.
- Confirm the final director composition and the terms of the four elected Class II directors.
- Review the voting results, including broker non-votes and the comparatively closer vote on officer exculpation.
- Assess any future implications of eliminating supermajority voting provisions for shareholder approval thresholds.
- Verify future financial performance and guidance in the Company’s periodic reports, as this 8-K contains no financial results.